A Bristol Myers drug that treats anemia caused by a type of blood cancer now has an FDA approval that moves it up in the hierarchy of treatments, expanding the eligible patient population and ...
Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results